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ABSTRACT
Over the years 1986-1997, at the Centre ot Oneology in Kraków, 82 patients (28 women, 54 men; mean age:
50.8 years) with poorly differentiatied naso- and oropharyngeal careinoma with metas18ses to regional nodes
(s18ge III and IV) received neoadjuvant chemotherapy tollowed by teleradiotherapy. The primary tumour was.
located in the nasopharynx in 57 patients (69.5%), in the tonsil .. in 24 (29.3%), and in the base of the tongue (one
patient). Chemotherapy cyeles consisted ot cisplatin in a dose ot 100 mg/m2 administered intravenously on the
first day, and 5-f1uorouracil in a dose of 1000 mglm2 over days 1 to 5. Forty-seven (57.3%) patients received 3
cycles, 25 (30.5%) patients - 2 cycles, 8 (9.8%) patients - 1 cycle. After chemotherapy, patients received
conventionally tractionated (200 cGy 5x a week) radiotherapy to the primary tumour (50-65 Gy) and regional
nodes (50-70 Gy). The therapy was generally well tolerated, however two patients developed tatal late
complications. Improvement in therapy results was observed when comparised with a historical group. Five-year
overall survival was 52%. The degree ot regression (PR + CR), tollowing neoadjuvant chemotherapy, which
appeared to depend on the number of ehemotherapy eycles, is the main prognostie tactor for this group ot
patients.
Poorly differentiated cancer (lymphoepithe-
lioma, unditferentiated carcinoma) is commonly
found in the naso- and oropharynx, although
its general incidenee in non-endemie areas is
rather low (Chan et al.,1998; Reddy et al.,
1995). In patients with poorly differentiated
eancer of naso- and oropharynx (POCNO),
even with a loeally advanced disease and
regional node involvement, it is relatively easy
to obtain loco-regional control of the disease
with adequate dose and tumour coverage.
About 20-30% of patients with a loco-regionally
eontrolled disease will eventually die of distant
metastases (Teo et aL, 1996). Thus, many
authors recommend adjuvant ehemotherapy in
node-positive patients with POCNO (AI-Sarraf
and McLaughlin, 1995; Chan et al., 1998;
Garden et al., 1996; Geara et al., 1997; Munro,
1995; Wong, 1998).
In the mid 'eighties, patients with POCNO
were treated at the Oncology Centre in Kraków
(Poland) by radiotherapy alone (years 1970 -
1980), or by radiotherapy combined with
neoadjuvant monochemotherapy using
methotrexate (years 1981 - 1985). Review of
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the results of these treatments indicated that
the clinical status ot the cervical nodes is an
independent prognostic factor. In the group of
patients with negative nodes (NO aeeording to
TNM UICC classitication, 1987), 3-year
disease-free survival was achieved in 86% of
the patients, while the respective ratios in
patients with nodal metastases N1, N2 and N3
were 57%, 21 % and 3% (Reinfuss et al., 1991;
Reinfuss, 1981).
Our observations are in accord with those of
other authors (Chan et al., 1998: Cheng et al.,
1998; Lee et al., 1992; Teo et al., 1996). We
have also found that distant metastases were
the cause of failure in 90% of aur patients. The
use of methotrexate in adjuvant therapy
neither improved the results of the treatment
nor changed the distribution ot the causes of
radiotherapy failures. Therefore, in positive -
node POCNO patients a study of radiotherapy
combined with neoadjuvant chemotherapy
(cisplatin and 5-fluorouracil) began in 1986
(Radkowski et al., 1997). In this paper we
present the updated results ot this study.
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MATERIAL ANO METHOOS
Over the years 1986 - 1997, eighty-two
patients (28 women and 54 men) with POGNO
with metastases to the cervical nodes were
treated tor the tirst time at the Oncology Centre
in Kraków. Their median age was 50.8 years
(14 - 76 years). Fifty-seven (69.5%) patients
had cancer ot the nasopharynx, 25 (30.5%) -
ot the oropharynx (in 24 patients the palatine
tonsil, in 1 patient the base ot the tongue were
involved). The performance status ot the
patients, on Karnotsky's scale, ranged
between 60 and 100 (median 80).
Twelve (14.6%) patients had stage T1
POGNO, 33 (40.2%) patients - T2, 19 (23.2%)
patients - T3 and 19 (22.0%) patients -T4. Ali
patients had metastatic cervical nodes, ot the
diameter ranging between 1 cm and 15 cm
(median 5.5 cm). In 10 (12.2%) ot these
patients the diameter ot the involved nodes did
not exceed 3 cm (N1), in 22 (26.8%) patients it
ranged between 3 cm and 6 cm (N2), and in
50 (60.0%) patients it exceeded 6 cm (N3).
The detailed clinical staging ot our patients is
presented in table 1.
Primary Tumour T4 TotalT1 T2 T3
Nodes
N1 1 2 2 5 10 (12.2%)
N2 4 10 8 O 22 (26.8%)
N3 7 21 9 13 50 (61.0%)
Total 12 (14.6%) 33 (40.2%) 19 (23.2%) 18 (22.0%) 82 (100%)
Table 1. Stage of disease in 82 patients with PDCNO treated by chemo- and radiotherapy.
Ghemotherap~ consisted ot cisplatin in a dose
ot 100 mg/m administered intravenously on
day 1, and 5-tluorouracil in a dose ot 1000
mg/m2 over days 1 through 5. Fluorouracil
was administered by intravenous intusion tor at
least 10 hours a day. Prior to each cycle ot
chemotherapy, complete blood count, and
biochemical tests ot the liver and kidney
efficiency were performed. The cycles ot
chemotherapy were applied with 3-week
intervals.
We initiaily planned to administer 2-3 cycles
ot chemotherapy depending on the degree ot
tumour remission and treatment tolerance.
Forty-seven (57.3%) patients received three
complete cycles ot chemotherapy, 25 (30.5%)
patients - 2 cycles, 8 (9.8%) patients - only one
cycle. Four (50%) ot the patients had partial
remission after only one cycle. After two cycJes
ot chemotherapy we observed partial
remission in 16 patients (64%) and in 6
patients (24%) complete remission. In 9 ot 33
patients (27.3%) we stopped chemotherapy
after10r 2 cycles because ot the toxicity G3-4.
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Two (2.4%) patients received 4 and 6 cycles
due to extended delay in commencing
radiotherapy.
Radiotherapy was initiated 3 - 4 weeks after
completion ot chemotherapy. In the tirst
phase, the whole pharynx was irradiated tor
tive weeks with 50 Gy in 25 tractionsby two
opposed cobalt-60 beams. Gervical nodes with
the larynx shielded were irradiated with 50 Gy
in 25 tractions by one anterior cobalt-60 beam.
In 69 (84.2%) patients the bed ot primary
tumour was turther irradiated to atotal dose ot
60 - 65 Gy. The involved cervical nodes were
irradiated by an additional dose ot 10 - 20 Gy
using electron beams ot 11 - 15 MeV.
The overall survival rate was calculated trom
the tirst day ot chemotherapy until the date ot
death or last toilow-up examination (censored
observation). Oisease-free survival rate was
calculated trom the day of complete regression
ot the disease evaluated by c1inical
examination until the tirst evidence ot disease
relapse, distant metastases, or last tollow-up
examination. For graphic presentation ot the
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survival rate, the Kaplan-Meier method was
used, for calculations - the Statsoft Statistica
programme. The accepted level of statistical
significance was P ~ 0.05.
RESULTS
At the end of our observation period, of the
82 patients treated, 53 patients were alive,
including 45 disease-free; 29 patients died, 6
without cancer (2 patients died of necrosis of
the posterior pharyngeal wall, one patient of
prostate carcinoma, one patient of malignant
Iymphoma, and two patients of circulatory
insufficiency). The median observation time
was 21 months, observation time ranging from
5 months to 105 months). Figure 1 shows the
follow-up of all 82 patients qualified for
treatment and figure 2 shows the overall and
disease-free survival curves of our patients.
Fifty-two percent of overall and forty-seven
percent of disease-free 5-year survival were
obtained.
82 patients
qualified for treatment
No. of cycles
1
2
3
4
6
No. of patients
8
25
47
1
1
2 patients not
~ qualified for radiotherapy
(1 pt developed complications,
1 pt progression of cancer)
I
80 patients
qualified for radiotherapy
I
78 patients
2 patients did not receive fuli dose
~ (1 pt24Gy-CR) l
(1 pt16Gy-PR)
completed radiotherapy (Le. tumour ~
dose =>40 Gy)
74 patients· eR
74 patients
alive NED - 45 pts Failures
alive with cancer - 8 pts T+N
-
9 pts
died of cancer -- 15 pts M -- 12 pts
died of other diseases
-
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- 2 pts
Fig. 1. Follow-up of 82 patients with PDCNO treated with chemo - and radiotherapy.
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Fig. 2. Overall survival and disease-free survival in a group of 82 patients with PDCNO.
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Fig. 3. Relation between number chemotherapy cycles and
regression ot tumour after chemotherapy.
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The effectiveness ot neoadjuvant
chemotherapy was high: in 18 (21.9%) patients
complete remission ot disease (GR), in 50
(61.0%) patients partial remission (PR), and in
11 (13.4%) patients disease stabilisation (MR
+ NC) were observed. In three (3.7%) patients
the disease progressed during chemotherapy.
In 68 (82.9%) patients with signiticant
response to chemotherapy (PR + GR), there
appeared to be a relation between the
percentage ot responses and the number ot
chemotherapy cycles. After one cycle only
4.9% ot partial remissions were observed,
while 19.5% and 35.4% ot partial remission
were seen after two and three cycles,
respectively. Gomplete remission ot disease
was obtained in 7.3% ot patients after two
cycles, and in 14.6% ot patients after three
cycles ot chemotherapy (Figure 3).
No. ot
patients 50
40
30
20
10
o
ilIMR OCR
2 3
No. ot chemotherapy
cycles
Toxicity N %
Vomiting (G3-4)* 4 4.9
Trombocytopenia «100 x1 09/1) 6 7.3
Leucopenia «2.0 x109/1) 3 3.7
Intection (treated with antibiotics) 4 4.9
Anaemia (transtusions) 3 3.7
Renal insufficiency 2 2.4
Exacerbation ot circulatory insufficiency 3 3.7
lncrease ot hepatic transaminase activity 1 1.2
* - toxicity scale according to WHO.
Table 3. Toxicity ot induction chemotherapy in 82 patients wilh PDCNO. leading to cessation ot lreatment or exlension ot lhe
interval belween chemotherapy cycles.
Most patients tolerated chemotherapy wall.
Only three patients had exacerbation ot
circulation insutficiency, causing a deterioration
ot their general condition. Further treatment ot
two ot these patients was discontinued.
Detailed intormation on the toxicity causing
cessation ot treatment or extension ot intervals
between chemotherapy cycles is shown in
table 3. The overall percentage ot serious
complications tollowing chemotherapy was
25.6%.
Seventy-eight (95.1 %) patients received
minimum combined therapy: at least one cycle
70
ot chemotherapy and radiotherapy dose 40 Gy
tor primary tumour and cervical nodes. During
the course ot teleradiotherapy 26 (31.7%)
patients developed cutaneous or mucosal
reaction G3, according to WHO intensity
classification (Beretta). In one patient,
irradiation was discontinued after a dose ot 40
Gy, due to hepatic metastases. The median
value ot the total dose to the primary tumour
was 60 Gy (mean: 60,2 Gy) and to the lymph
nodes - 58 Gy (mean: 58,5 Gy). Thirty-tive
(44.9%) patients maintained the same body
weight during the course ot treatment, 36
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(46.1 %) pat~ents lost weight within 5% and 7
(9.0%) - within 5% and 10%. Two patients
died ot necrosis ot the posterior pharyngeal
wall, 10 and 30 months after radiotherapy,
respectively.
After the tuli course ot therapy, 74 patients
had complete locoregional remission (CR)
(figure 1). Out of 74 complete responders 19
(25.7%) patients developed locoregional
recurrence: 13 (17.6%) ot these in cervical
Iymph nodes, 4 (5.4%) at the primary site and
two (2.7%) both in the primary site and cervical
Iymph nodes. Ot 13 patients with recurrence in
cervical Iymph nodes, 10 patients were
successtully treated with rescue surgery,
surgery and re-irradiation, or re-induction and
surgery. In 15 of 82 patients distant
metastases were diagnosed, Le. in 14 ot 74
patients with CR, and in one patient ot 8
without CR. The metastases occurred in:
bones (31.8%), liver (22.7%), central nervous
system (9.0%), peripheral Iymph nodes (9.0%),
and lungs (4.6%).
In single - or multi-variable analysis, we
investigated the influence on the overall
survival ot: sex, age, Karnotsky's performance
status, site ot the primary tumour, stage of
disease, size of involved nodes, location of the
nodes, and response to neoadjuvant
chemotherapy.
In single-variable analysis, signiticanUy poorer
results were obtained in patients with primary
tumour stage T4, nodal involvement N3, and in
patients with progression or stabilisation ot
disease after chemotherapy (P, NC, MR).
Detailed results are listed in table 2. The most
important tactor negatively intluencing the
prognosis ot outcome in multivariable analysis
was lack of regression of the disease after
neoadjuvant chemotherapy.
Population and clinical
teatures or treatment
Total:
Sex:
Female
Male
Age:
:S;39 years
>39 years
Karnofsky's performance status:
<80%
~80%
Site:
nasopharynx
oropharynx
Primary tumour*:
T 1 - 3
T4
Nodes*:
N 1 - 2
N3
Node site:
Upper
Lower
Size ot bulky nodes:
1 - 8 cm.
>8cm.
Number ot Probability ot overall
patients 5-year survival
82 52.0
28 58.0
54 46.0
17 61.0
65 49.0
23 31.0
59 61.0
57 49.0
25 58.0
64 65.0
18 21.0
32 83.0
50 39.0
62 54.0
20 44.0
69 56.0
13 33.0
Statistical
signiticance
p = 0.29
p = 0.66
p = 0.08
p=0.9
p = 0.008
p = 0.005
p = 0.08
p = 0.25
*assessed according to UICC (Beretta).
Table 2. 5-year overall survival versus clinical characteristics and response to chemotherapy.
Number ot chemotherapy cycles:
1
2-3
Response after chemotherapy:
MR, NC, P
CR, PR
8
74
14
68
45.0
51.0
29.0
60.0
p = 0.61
p = 0.007
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DISCUSSION
The group studied consisted of 82 patients
with POCNO with cervical node involvement
(N1 - 3), with median 5.5 cm of diameter. In
this group, 52% of the overall 5-year actuarial
survival rate and 47% of disease-free survival
rate were achieved using combined
neoadjuvant chemo- and radiotherapy. In
comparison with a historical group of patients
with disease at a similar stage, treated in the
years 1970 - 1985 with radiotherapy alone or
radiotherapy combined with adjuvant
monochemotherapy using methotrexate, 3-
year disease-free survival was obtained in 22%
of the patients. The observed improvement of
the results of treatment appears to be of
clinical importance. This improvement was
related to the reduced risk of distant
metastases. However, it should be empha-
sised that our investigations are stil! at an
experimental stage. POCNO is a relatively
rare neoplasm, therefore we have to base our
comparison on a historical group, which is of
Iimited value.
It is difficult to compare our results with those
of other authors, due to the immense diversity
of the groups studied (Lee et aL, 1992; Garden
et aL, 1996; Geara et aL, 1997). Nevertheless,
we note that neoadjuvant chemotherapy is
becoming increasingly applied in the case of
advanced carcinoma of the head and neck,
and it is especially recommended for poorly
differentiated nasopharyngeal - type carcinoma
(Chan et a1.1998; Munro, 1995). Attempts to
use a new system of dose fractionation in
POCNO have not improved the results, since
over 80% of patients die mainly due to
metastatic spread (Lee et aL, 1992; Chan et
aI.1998). The role of neoadjuvant chemothe-
rapy in nasopharygeal carcinoma has been
examined in three randomized triais. In each
trial a different approach was used with respect
to drug combinations, time sequence of
chemotherapy and radiotherapy admi-
nistration, and radiotherapy technique and
dose. In the chemotherapy arm a tendency to
reduce the incidence of recurrences and
improvement of disease-free survival were
seen in the subgroup of patients with bulky
neck Iymph nodes greater than 6 cm (Chua
et aL, 1998; Chan et aL, 1995; International
Nasopharynx Cancer Study Group). The only
trial to date that has shown any improvement
in overall survival with the addition of
chemotherapy is the recently completed Head
and Neck Intergroup trial (AI.-Sarraf et
al.,1995; Fu KK, 1998). One hundred and
forty-seven patients with stage III and IV
nasopharynx carcinoma were randomized to
72
receive radiotherapy plus concurrent as well as
adjuvant chemotherapy or radiotherapy alone.
3-year progression-free survival rates were
significantly higher in the combined therapy
group (69% versus 24%), P<.001), as well as
the overall survival rates (78% versus 47%, P
=.002).
Several authors concur with our observation
that the level of regression of disease following
neoadjuvant chemotherapy is the main
prognostic factor (Garden et aL, 1996; Geara
et aL, 1997). aur studies suggest that the
possibility of achieving CR or PR is directly
related to the number of given chemotherapy
cycles.
In the group studied, we used neoadjuvantly
cisplatin combined with 5-fluorouracil. Other
authors used combinations of various
therapeutic agents including doxorubicin,
bleomycin, methotrexate, 5-fluorouracil,
cisplatin, vinblastin, and epirubicin (Chua et aL,
1998; Chan et aL, 1998). Further investigations
should follow, to develop the optimum time
combinations of chemo- and radiotherapy, the
most effective chemotherapy regimen, and the
most appropriate target group.
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